Shanu Modi

An update on epidermal growth factor receptor inhibitors.

Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.

Single-agent gemcitabine in the treatment of advanced breast cancer.

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Preoperative chemotherapy for breast cancer: miracle or mirage?

HER2 breast cancer therapies: a review.

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.

HSP90 inhibitors for cancer therapy and overcoming drug resistance.

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer.

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.